TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05261464

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol tartrate
Description: Prescribe oral metoprolol tartrate according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Prescribe oral ivabradine according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Prescribe oral diltiazem immediate-release according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
Study: NCT06367400

Intervention type: DIAGNOSTIC_TEST
Intervention: Pediatric Sleep Questionnaire
Description: Questionnaire with 22 questions of symptoms of OSDB
Study: NCT05993156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: modified Fixed twinblock
Description: modified fixed twin block functional appliance, with cemented bands on the first molars

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: removable twin block
Description: Conventional Removable Clark twin block myofunctional appliance
Study: NCT05909124

Intervention type: DEVICE
Intervention: MCE
Description: underwent MCE examination

Intervention type: DEVICE
Intervention: MCE
Description: underwent MCE examination
Study: NCT06025838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: positive feedback
Description: The positive feedback game uses techniques relating to established therapies like Behavioral Activation and Acceptance and Commitment Therapy's valued living to encourage positive action in game and outside of the game.
Study: NCT06242288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ISOtretinoin 20 MG
Description: Isotretinoin, also known as 13-cis-retinoic acid and sold under the brand name Accutane among others, is a medication primarily used to treat severe acne
Study: NCT06177600

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interactive educational digital platform for transgender and gender-diverse (TGD) young adults and caregivers
Description: Investigators will develop a free mobile- and web-enabled platform for TGD young adults and their caregivers that combines educational modules with high-quality, evidence-based information and interactive features. At the time of account creation, users will complete an intake survey that will be used to personalize platform features. Young adults will be asked about their goals; mental health; access to health care; degree of caregiver support; and sociodemographic characteristics. Caregivers will be asked about their goals and self-assessed level of supportiveness of their young adults.~Users will be assigned educational modules that build knowledge and skills related to improving mental health and navigating relationships and communication with others. Both exposure to and completion of modules will be tracked.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive educational digital platform for transgender and gender-diverse (TGD) young adults and caregivers
Description: Investigators will develop a free mobile- and web-enabled platform for TGD young adults and their caregivers that combines educational modules with high-quality, evidence-based information and interactive features. At the time of account creation, users will complete an intake survey that will be used to personalize platform features. Young adults will be asked about their goals; mental health; access to health care; degree of caregiver support; and sociodemographic characteristics. Caregivers will be asked about their goals and self-assessed level of supportiveness of their young adults.~Users will be assigned educational modules that build knowledge and skills related to improving mental health and navigating relationships and communication with others. Both exposure to and completion of modules will be tracked.
Study: NCT06066541

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Scorecard
Description: Participants will be mailed a scorecard from Humana reporting patients' medication adherence using a refill score.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scorecard
Description: Participants will be mailed a scorecard from Humana reporting patients' medication adherence using a refill score.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scorecard
Description: Participants will be mailed a scorecard from Humana reporting patients' medication adherence using a refill score.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social norms
Description: Participants will be mailed a dynamic social norms messaging (noting the proportion of Humana members improving their medication refill scores).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social norms
Description: Participants will be mailed a dynamic social norms messaging (noting the proportion of Humana members improving their medication refill scores).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messenger effects
Description: Participants will be mailed a scorecard coming from the trusted messenger of a Humana-identified pharmacist taking the same medication.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messenger effects
Description: Participants will be mailed a scorecard coming from the trusted messenger of a Humana-identified pharmacist taking the same medication.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Processing fluency
Description: Participants will be mailed a modified scorecard increasing processing fluency through a visual metaphor of closing the ring.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Processing fluency
Description: Participants will be mailed a modified scorecard increasing processing fluency through a visual metaphor of closing the ring.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Processing fluency
Description: Participants will be mailed a modified scorecard increasing processing fluency through a visual metaphor of closing the ring.
Study: NCT06116409

Intervention type: DRUG
Intervention: Bupivacain
Description: Bupivacaine was used for postoperative analgesia block.
Study: NCT05839613

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Therapeutic Drug Monitoring (TDM) and Pharmacogenetics (PG)
Description: Pharmacogenetics (PG) is the study of genetic differences in drug met-abolic pathways Therapeutic Drug Monitoring (TDM) is the quantification and interpre-tation of drug concentration in blood to optimize pharmacotherapy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Therapeutic Drug Monitoring (TDM) and Pharmacogenetics (PG)
Description: Pharmacogenetics (PG) is the study of genetic differences in drug met-abolic pathways Therapeutic Drug Monitoring (TDM) is the quantification and interpre-tation of drug concentration in blood to optimize pharmacotherapy
Study: NCT06127498

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A8G6 SARS-CoV-2 Neutralization Antibody combination nasal spray
Description: Subjects in each cohort were randomly assigned 5:1 to two parallel administration groups, one of which served as a control. Each cohort was given either the experimental drug or placebo by nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose. Right nostril and nasal swabs were collected for immunotoxicity, immunogenicity (immunogenicity collection and detection in cohorts 3 and 4 only), and drug concentration detection. Subjects in the first three cohort were required to return to the study Center 3±1 days after the last dose for blood samples, bilateral nostril and nasal swabs for drug concentration, immunotoxicity, physical examination, vital signs, and safety laboratory indicators (blood routine, blood biochemical, and urine routine). Subjects in cohort 4 returned to the study center 7±2 days after the last dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: A8G6 SARS-CoV-2 Neutralization Antibody nasal excipient
Description: Subjects in each cohort were randomly assigned 5:1 to two parallel administration groups, one of which served as a control. Each cohort was given either the experimental drug or placebo by nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose. Right nostril and nasal swabs were collected for immunotoxicity, immunogenicity (immunogenicity collection and detection in cohorts 3 and 4 only), and drug concentration detection. Subjects in the first three cohort were required to return to the study Center 3±1 days after the last dose for blood samples, bilateral nostril and nasal swabs for drug concentration, immunotoxicity, physical examination, vital signs, and safety laboratory indicators (blood routine, blood biochemical, and urine routine). Subjects in cohort 4 returned to the study center 7±2 days after the last dose.
Study: NCT05332015

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypotonic (distilled) water
Description: orally given daily two liters of distilled water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal water
Description: orally given daily two liters of normal water
Study: NCT05641909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Dosage forms and strengths: 50 mcg/mL Fentanyl base/10 mL ampules. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
Study: NCT05627427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: 250mg, p.o., qd, q3w, until disease progression or other treatment termination criteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg, IV, D1, q3w, until disease progression or other treatment termination criteria
Study: NCT06234670

Intervention type: OTHER
Intervention: No intervertion
Description: This study is a retrospective observational study without intervention.
Study: NCT04855786

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic duct drainage
Description: drain placement into the thoracic duct
Study: NCT05702424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGM-7354
Description: IGM-7354 is a PD-L1-targeted cytokine that is designed to regulate T and natural killer cell activation, proliferation and promote their anti-tumor effects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGM-7354
Description: IGM-7354 is a PD-L1-targeted cytokine that is designed to regulate T and natural killer cell activation, proliferation and promote their anti-tumor effects
Study: NCT05554822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 100mg
Description: Single antiplatelet therapy with aspirin 100 mg OD for 6 months after the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100 mg OD plus clopidogrel 75 mg OD
Description: Double antiplatelet therapy with Aspirin 100 mg OD plus clopidogrel 75 mg OD for 3 months, followed by 3 months of single antiplatelet therapy with aspirin 100 mg OD.
Study: NCT04929626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate 500 mg/ml+ ventolin
Description: 3 doses of magnesium sulphate i.e; 250mg(0.5ml), 500mg(1ml), 750mg(1.5ml) will be used in nebulized form

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ventolin
Description: it will be given to control group in nebulized form after every 20 min in 1st hour
Study: NCT06374459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zumsemetinib
Description: Patients should take zunsemetinib at approximately the same times every day, with or without food with 8 oz of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zumsemetinib
Description: Patients should take zunsemetinib at approximately the same times every day, with or without food with 8 oz of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zumsemetinib
Description: Patients should take zunsemetinib at approximately the same times every day, with or without food with 8 oz of water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Patients should take capecitabine at approximately the same times every day, within 30 minutes after a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Patients should take capecitabine at approximately the same times every day, within 30 minutes after a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Patients should take capecitabine at approximately the same times every day, within 30 minutes after a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Patients should take capecitabine at approximately the same times every day, within 30 minutes after a meal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: Standard of care. Will receive zoledronic acid or denosumab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Standard of care. Will receive zoledronic acid or denosumab.
Study: NCT06185790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LCHF diet
Description: Low-carb high-fat (LCHF) diet
Study: NCT06426056

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Image guidance volume modulated arc therapy included 50.4 Gy in 28 fractions to the pelvis and 59.4 Gy simultaneous boost in 28 fractions to involved pelvic and para-aortic lymph nodes, and subsequent high-dose-rate intracavitary brachytherapy at a total dose of 30.0-36.0 Gy in 5-6 fractions, twice a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Concurrent chemotherapy regimen included weekly cisplatin (40 mg/m\^2) and weekly nab-paclitaxel at escalating doses (33 mg/m\^2 per week).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Concurrent chemotherapy regimen included weekly cisplatin (40 mg/m\^2) and weekly nab-paclitaxel at escalating doses (33 mg/m\^2 per week).
Study: NCT06484114

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Revita Duodenal Mucosal Resurfacing (DMR)
Description: DMR is designed to ablate and re-epithelialize the duodenal mucosal surface, thus allowing nutrients to be exposed to a newly regrown and potentially normalized local mucosa. This implies that the duodenal mucosa surface is abnormal in participants associated with metabolic disorders. The Revita DMR procedure is performed endoscopically with supporting fluoroscopy.

Intervention type: DEVICE
Group type: OTHER
Intervention: Revita Duodenal Mucosal Resurfacing (DMR)
Description: DMR is designed to ablate and re-epithelialize the duodenal mucosal surface, thus allowing nutrients to be exposed to a newly regrown and potentially normalized local mucosa. This implies that the duodenal mucosa surface is abnormal in participants associated with metabolic disorders. The Revita DMR procedure is performed endoscopically with supporting fluoroscopy.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: An endoscopic review with non active catheter introduction
Study: NCT02912897

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellular therapy with EBV specific autologous CTL infusion
Description: CTL infusions at D0, M3 and M6
Study: NCT04992052

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone wax
Description: The surgeons will apply the bone wax to the exposed cancellous bone after the implant has been cemented in place in patients randomized to the treatment arm.
Study: NCT04114448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: Patients will perform an exercise protocol specifically designed for patients with hemophilia that will include exercises focused on improving range of movement, strength, flexibility, balance and coordination as well as diaphragmatic breathing at the start and at the beginning of each session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual physical therapy care
Description: Patients will undergo usual physical therapy treatment for hemophiliacs, based on affected self and gentle joint mobilization and stretching of muscles involved in the affected joints.
Study: NCT05586009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin with hydration magnesium
Description: Optimal doses of magnesium in prevention cisplatin induced nephrotoxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin with hydration magnesium
Description: Optimal doses of magnesium in prevention cisplatin induced nephrotoxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin with hydration magnesium
Description: Optimal doses of magnesium in prevention cisplatin induced nephrotoxicity
Study: NCT05873023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing gum
Description: chewing gum everyday for 12 weeks. Alternate chewing for 10 minutes on the right and 10 minutes on the left.
Study: NCT04776551

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous fixation of acute Scaphoid fractures
Description: Percutaneous Trans-trapezial fixation of acute Scaphoid fractures by Herbert screw
Study: NCT05739045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab combined with SOX
Description: nivolumab + SOX (3 cycles) before surgery → radical surgery (D2) → nivolumab + SOX (3 cycles) after surgery → nivolumab monotherapy maintenance (11 cycles);
Study: NCT06115369

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medically Tailored Meals Delivered Conditionally
Description: Season Health, our food intervention partner, will provide participants with weekly deliveries of twice-daily prepared medically tailored meals (MTM). Participants will receive this supplement conditioned on continued participation and engagement in their healthcare, including attending all scheduled office visits and refilling prescription medications. If participants do not refill their prescriptions or do not attend their office visits, the shipments of medically tailored meals will be paused. These will be restarted when the participant's appointment is rescheduled or when the participant's prescription is refilled.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medically Tailored Meals Delivered Unconditionally
Description: Season Health, our food intervention partner, will provide participants with weekly deliveries of twice-daily prepared medically tailored meals (MTM). Participants will receive this supplement unconditionally for the entire study duration.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Produce Boxes delivered Conditionally
Description: Season Health, our food intervention partner, will provide participants with weekly deliveries of fresh produce and pantry staples. Participants will receive this supplement conditioned on continued participation and engagement in their healthcare, including attending all scheduled office visits and refilling prescription medications. If participants do not refill their prescriptions or do not attend their office visits, the shipments of medically tailored meals will be paused. These will be restarted when the participant's appointment is rescheduled or when the participant's prescription is refilled.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Produce Boxes Delivered Unconditionally
Description: Season Health, our food intervention partner, will provide participants with weekly deliveries of fresh produce and pantry staples. Participants will receive this supplement unconditionally throughout the entire study period.
Study: NCT05688514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innovalve MR system
Description: Innovalve MR system
Study: NCT05932095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TCM Daoyin
Description: The TCM Daoyin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 12-weeks. All sessions included 10 min of warmup and 10 min of cooldown.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education
Description: Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.
Study: NCT05998642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 3.5mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab (where available)
Description: 375mg/m2 / 1400mg IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Dose and schedule assigned at enrollment
Study: NCT04815902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: Oral Fisetin 20 mg/kg taken for 10 days total.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fisetin
Description: Oral Fisetin 20 mg/kg taken for 10 days total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: 12.5 mg oral Losartan taken for 30 days total.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: 12.5 mg oral Losartan taken for 30 days total.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo - Losartan
Description: Losartan appearance-matched microcrystalline cellulose placebo. 12.5 taken for 30 days total.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Losartan
Description: Losartan appearance-matched microcrystalline cellulose placebo. 12.5 taken for 30 days total.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Fisetin
Description: Fisetin appearance-matched microcrystalline cellulose placebo. 20 mg/kg taken for 10 days total.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Fisetin
Description: Fisetin appearance-matched microcrystalline cellulose placebo. 20 mg/kg taken for 10 days total.
Study: NCT05116930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: IV infusion 20 μg/kg over 10 minutes repeated every 8 hours for a maximum of 3 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: IV infusion 4 μg/kg over 10 minutes repeated every 8 hours for a maximum of 3 doses